Mesoblast (MESO) Tax Provisions (2016 - 2023)
Mesoblast (MESO) posted Tax Provisions of -$40000.0 for Q2 2023, up 13.04% sequentially from -$46000.0 in Q1 2023, and up 23.08% YoY from -$32500.0 in Q2 2022.
Powered by 
Analysis
Mesoblast (MESO) Tax Provisions (2016 - 2023) Analysis & Trends
Mesoblast has reported Tax Provisions for 7 years, with the latest figure at -$40000.0 in Q2 2023.
- Quarterly Tax Provisions rose 23.08% year-over-year to -$40000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was -$212000.0 (up 11.3% YoY) and the FY2025 annual result came in at $330000.0, up 272.77% from the prior year.
- Tax Provisions improved to -$40000.0 in Q2 2023 per MESO's latest filing, from -$46000.0 in the prior quarter.
- Over five years, Tax Provisions peaked at $74000.0 in Q4 2020 and troughed at -$3.3 million in Q2 2020.
- A 5-year average of -$892500.0 and a median of -$75500.0 in 2021 frame the typical range for Tax Provisions.
- The sharpest annual moves came in 2019 and 2020: Tax Provisions slumped 211.17% in 2019, then surged 103.26% in 2020.
- Over 5 years, Tax Provisions stood at -$2.3 million in 2019, then soared by 103.26% to $74000.0 in 2020, then tumbled by 208.11% to -$80000.0 in 2021, then gained by 11.25% to -$71000.0 in 2022, then surged by 43.66% to -$40000.0 in 2023.
- According to Business Quant data, Tax Provisions over the past three periods registered -$40000.0, -$46000.0, and -$71000.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | -384,000.00 |
| Mar 31, 2023 | 46,000.00 |
| Dec 31, 2022 | 71,000.00 |
| Sep 30, 2022 | 55,000.00 |
| Jun 30, 2022 | -426,000.00 |
| Mar 31, 2022 | 45,000.00 |
| Dec 31, 2021 | 80,000.00 |
| Sep 30, 2021 | 62,000.00 |
| Jun 30, 2021 | -1.57 Mn |
| Mar 31, 2021 | 98,000.00 |
| Dec 31, 2020 | -74,000.00 |
| Sep 30, 2020 | 730,000.00 |
| Mar 31, 2020 | 6.16 Mn |
| Dec 31, 2019 | 4.20 Mn |
| Sep 30, 2019 | 1.93 Mn |
| Jun 30, 2019 | 3.18 Mn |
| Mar 31, 2019 | 2.21 Mn |
| Dec 31, 2018 | 2.87 Mn |
| Sep 30, 2018 | 711,000.00 |
| Jun 30, 2018 | 1.02 Mn |